- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe active rheumatoid arthritis; Ankylosing spondylitis; Severe psoriatic arthritis; Severe chronic plaque psoriasis
- Meeting Date: December 2020
- Public Summary Document (PSD) September 2020 PBAC Meeting - (PDF 595KB)
- Public Summary Document (PSD) September 2020 PBAC Meeting - (Word 31KB)
Etanercept – December 2020
Etanercept: Injection 50 mg in 1 mL single use auto-injector, 4; Injections 50 mg in 1 mL single use pre-filled syringes, 4; Brenzys®
Last updated
23 April 2021